Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it has been notified that Dr. Steven Gillis, Non-Executive Director of the Company, was recently informed that American Depositary Shares (“ADSs”), as set out below, were acquired on his account by an independent third party exercising discretion over dealing decisions. The transactions took place on the NASDAQ.
|Date of transaction||Number of ADSs acquired||Average price per ADS|
|October 30, 2014||127||$196.744|
|December 19, 2014||76||$218.16|
Following the above transactions, Dr. Gillis holds 674 ADSs. One ADS is equal to three ordinary shares of 5 pence each in the Company.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules (“DTRs”). In accordance with 3.1.5(R) of the DTRs, the information required to be included in this notification was received by the Company today, January 8, 2015.
+1 781 482 0945
+44 1256 894157
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
Click here for the PDF version of this press release.